Current Urology Reports

, Volume 4, Issue 5, pp 385–390 | Cite as

Update on overactive bladder: Pharmacologic approaches on the horizon

  • Eric S. Rovner
  • Alan J. Wein
Article

Abstract

Limitations exist with regard to the array of available agents for the pharmacologic therapy of overactive bladder, including issues of efficacy and tolerability. It is clear that the ideal agent for this condition has not been identified. However, several new pharmacologic treatments, including some with novel approaches to drug delivery, have emerged in clinical development over the past few years. These agents include a variety of anticholinergics and others. In initial studies, some of the agents appear to compare favorably with existing therapies. Whether these promising results will hold up when subjected to large-scale, well-controlled clinical trials is unclear.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Diokno AC, Lapides J: Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 1972, 108:307–309.PubMedGoogle Scholar
  2. 2.
    Rovner ES, Wein AJ: Modern pharmacotherapy of urge urinary incontinence in the U.S.: tolterodine and oxybutynin. Br J Urol 2000, 86:44–54.Google Scholar
  3. 3.
    Wein AJ: Neuromuscular dysfunction of the lower urinary tract and its management. In Campbell’s Urology, edn 8. Edited by Walsh PC, Retik A, Vaughan ED Jr, et al. Philadelphia: WB Saunders; 2002.Google Scholar
  4. 4.
    Andersson KE, Appell RA, Cardozo L, et al.: Pharmacological treatment of urinary incontinence. In Incontinence. Edited by Abrams P, Khoury S, Wein AJ. Plymouth, UK: Heath Publication Ltd; 1999:447–486.Google Scholar
  5. 5.
    Hay-Smith J, Herbison P, Ellis G, Moore K: Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002, 3:CD003781.PubMedGoogle Scholar
  6. 6.
    Yoshimura N, Chancellor MB: Current and future pharmacological treatment for overactive bladder. J Urol 2002, 168:1897–1913. This is a comprehensive review of many of the preclinical and clinical studies of potential pharmacologic therapies for overactive bladder. Included is an interesting discussion of future (theoretical) potential advances, including gene therapy.PubMedCrossRefGoogle Scholar
  7. 7.
    Sellers DJ, Chapple CR, Chess-Williams R: Potential therapeutic targets for treatment of the overactive bladder. World J Urol 2001, 19:307–311.PubMedCrossRefGoogle Scholar
  8. 8.
    Rovner ES, Wein AJ: Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Eur Urol 2002, 41:6–14.PubMedCrossRefGoogle Scholar
  9. 9.
    Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine oncedaily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414–421.PubMedCrossRefGoogle Scholar
  10. 10.
    Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge incontinence. J Urol 1999, 16:1809–1812.Google Scholar
  11. 11.
    Gupta SK, Sathyan G: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999, 39:289–296.PubMedGoogle Scholar
  12. 12.
    Buyse G, Waldeck K, Verpoorten C, et al.: Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998, 160:892–896.PubMedCrossRefGoogle Scholar
  13. 13.
    Hughes KM, Lang JC, Lazare R, et al.: Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992, 22:859–869.PubMedGoogle Scholar
  14. 14.
    Waldeck K, Larsson B, Andersson KE: Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997, 157:1093–1097.PubMedCrossRefGoogle Scholar
  15. 15.
    Davila GW, Daugherty CA, Sanders SW, et al.: A short-term, multicenter, randomized, double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001, 166:140–145. Represents the initial peer-reviewed publications on the use of transdermal antimuscarinic therapy for overactive bladder.PubMedCrossRefGoogle Scholar
  16. 16.
    Dmochowski RR, Davila GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580–586. Represents the initial peer-reviewed publications on the use of transdermal antimuscarinic therapy for overactive bladder.PubMedCrossRefGoogle Scholar
  17. 17.
    Dmochowski R, Davila W, Sanders S: Transdermal oxybutynin and controlled release oral tolterodine in patients with positive treatment effect to anticholinergic therapy for overactive bladder. Neurourol Urodyn 2002, 21:380–381.Google Scholar
  18. 18.
    Brendler CB, Radebaugh LC, Mohler JL: Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989, 141:1350–1352.PubMedGoogle Scholar
  19. 19.
    O’Flynn KJ, Thomas DG: Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. Br J Urol 1993, 723:566–570.CrossRefGoogle Scholar
  20. 20.
    Boone TB, Appell RA, Lopez MA, et al.: Pharmacokinetics evaluation of intravesical oxybutynin: bolus and continuous delivery. J Urol 2001, 165:252–253.Google Scholar
  21. 21.
    Pietzko A, Dimpfel W, Schwantes U, Topfmeier P: Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994, 47:337–343.PubMedCrossRefGoogle Scholar
  22. 22.
    Hofner K, Oelke M, Machtens S, Grunewald V: Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyper-reflexia. World J Urol 2001, 19:336–343. This is a well-written summary of the up-to-date clinical studies on trospium.PubMedCrossRefGoogle Scholar
  23. 23.
    Hawthorn MH, Chapple CR, Cock M, Chess-Williams R: Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 2000, 129:416–419.PubMedCrossRefGoogle Scholar
  24. 24.
    Cardozo L, Chapple CR, Toozs-Hobson P, et al.: Efficacy of trospium chloride in patient with detrusor instability: a placebo-controlled, randomized, double blind, multicentre clinical trial. BJU Int 2000, 85:659–664.PubMedCrossRefGoogle Scholar
  25. 25.
    Stohrer M, Bauer P, Giannetti BM, et al.: Effect of trospium chloride on urodynamic parameters n patients with detrusor hyper-reflexia due to spinal cord injuries: a multicentre, placebo-controlled, double-blind trial. Urol Int 1991, 47:138–143.PubMedCrossRefGoogle Scholar
  26. 26.
    Alloussi S, Laval KU, Eckert R, et al.: Trospium chloride in a patient with motor urge syndrome (detrusor instability): a double-blind, randomized, multicentre, placebo-controlled study. J Clin Res Drug Dev 1998, 1:439–451.Google Scholar
  27. 27.
    Hofner K, Halaska M, Primus G, et al.: Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: a double-blind, controlled, multicentre clinical trial. Neurourol Urodyn 2000, 19:487–488.Google Scholar
  28. 28.
    Donnellan CA, Fook L, McDonald P, Playfer JR: Oxybutynin and cognitive dysfunction. BMJ 1997, 315:1363–1364.PubMedGoogle Scholar
  29. 29.
    Katz IR, Sands LP, Bilker W, et al.: Identification of medications that can cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998, 46:8–13.PubMedGoogle Scholar
  30. 30.
    Newgreen DT, Anderson DW, Carter AJ, et al.: Darifenacin: a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995, 14:555–557.Google Scholar
  31. 31.
    Braverman AS, Ruggieri MR, Pontari MA: The M2 muscarinic receptor subtype mediates cholinergic bladder contractions in patients with neurogenic bladder dysfunction. J Urol 2001, 165:36.Google Scholar
  32. 32.
    Braverman AS, Tallarida RJ, Ruggieri MR: Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol Regul Integr Comp Physiol 2002, 283:1–6.Google Scholar
  33. 33.
    Rosario DJ, Cutinha PE, Chapple CR: The effects of single-dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur Urol 1996, 30:240.Google Scholar
  34. 34.
    Chapple CR, Arano P, Bosch JH, et al.: YM 905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo and tolterodine controlled phase II dose finding study. Neurourol Urodyn 2002, 21:381–382.Google Scholar
  35. 35.
    Norton P, Zinner N, Yalcin I, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence. Neurourol Urodyn 2001, 20:532–534.Google Scholar
  36. 36.
    MacMahon SB, Spillane K: Brain stem influences on the parasympathetic supply to the urinary bladder of the cat. Brain Res 1982, 234:237–249.CrossRefGoogle Scholar
  37. 37.
    Espey MJ, Downie JW: Serotonergic modulation of cat bladder function before and after spinal transection. Eur J Pharmacol 1995, 287:173–177.PubMedCrossRefGoogle Scholar
  38. 38.
    Thor KB, Katofiasc MA: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995, 274:1014–1024.PubMedGoogle Scholar
  39. 39.
    Zinner N, Dmochowski R, Miklos J, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI). Neurourol Urodyn 2002, 21:383–384.Google Scholar
  40. 40.
    Schurch B, Stohrer M, Kramer G, et al.: Botulinum-A toxin for treating detrusor hyper-reflexia in spinal cord injured patients: A new alternative to anticholinergic drug? Preliminary report. J Urol 2000, 164:692–697.PubMedCrossRefGoogle Scholar
  41. 41.
    Yamaguchi O: _3 Adrenoreceptors in human detrusor muscle. Urology 2002, 59:25–29.PubMedCrossRefGoogle Scholar
  42. 42.
    Takeda M, Obara K, Mizusawa T, et al.: Evidence for _3 adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 1999, 288:1367–1373.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Eric S. Rovner
    • 1
  • Alan J. Wein
  1. 1.Division of UrologyHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations